NCT02255812

Brief Summary

Taste physiology describes five main taste qualities in humans: sweet, sour, salty, umami and bitter. The receptors found on the tongue are also found in the entire gut. The correlation of stimulation of these gut receptors and brain activity has not yet been examined. The objectives are to investigate the effect of different taste substances on i) regional brain activity and ii) satiation peptide release.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
12

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Mar 2013

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2013

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2013

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2013

Completed
10 months until next milestone

First Submitted

Initial submission to the registry

August 6, 2014

Completed
2 months until next milestone

First Posted

Study publicly available on registry

October 3, 2014

Completed
Last Updated

October 3, 2014

Status Verified

September 1, 2014

Enrollment Period

7 months

First QC Date

August 6, 2014

Last Update Submit

September 30, 2014

Conditions

Outcome Measures

Primary Outcomes (1)

  • regional brain activity assessed by functional Magnetic Resonance Imaging (fMRI)

    Changes in resting state functional connectivity

    changes from baseline to one hour after treatment

Secondary Outcomes (2)

  • gastrointestinal satiation peptide secretion

    changes from baseline to one hour after treatment

  • glucose and insulin secretion

    changes from baseline to one hour after treatment

Study Arms (6)

200 mL tap water

PLACEBO COMPARATOR

Single intragastric instillation of 200 mL tap water via nasogastric tube

Dietary Supplement: Single intragastric instillation of 200 mL tap water via nasogastric tube

2 g citric acid

ACTIVE COMPARATOR

Single intragastric instillation of 2 g citric acid in 200 mL tap water via nasogastric tube

Dietary Supplement: Single intragastric instillation of 2 g citric acid in 200 mL tap water via nasogastric tube

2 g salt

ACTIVE COMPARATOR

Single intragastric instillation of 2 g salt in 200 mL tap water via nasogastric tube

Dietary Supplement: Single intragastric instillation of 2 g salt in 200 mL tap water via nasogastric tube

0.017 g quinine

ACTIVE COMPARATOR

Single intragastric instillation of 0.017 g quinine in 200 mL tap water via nasogastric tube

Dietary Supplement: Single intragastric instillation of 0.017 g quinine in 200 mL tap water via nasogastric tube

1 g monosodium glutamate

ACTIVE COMPARATOR

Single intragastric instillation of 1 g monosodium glutamate in 200 mL tap water via nasogastric tube

Dietary Supplement: Single intragastric instillation of 1 g monosodium glutamate in 200 mL tap water via nasogastric tube

25 g glucose

ACTIVE COMPARATOR

Single intragastric instillation of 25 g glucose in 200 mL tap water via nasogastric tube

Dietary Supplement: Single intragastric instillation of 25 g glucose in 200 mL tap water via nasogastric tube

Interventions

Eligibility Criteria

Age18 Years - 45 Years
Sexmale
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • right-handed healthy males
  • Body-mass index of \< 25
  • Age 18-45 years
  • no drugs
  • non-smoking

You may not qualify if:

  • Smoking
  • Substance abuse
  • Regular intake of medications (except for oral contraceptives)
  • Medical or psychiatric illness, especially: diabetes, pace-maker, claustrophobia
  • History of gastrointestinal disorders
  • Food allergies, glutamate intolerance
  • Body piercings that cannot be removed

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University Hospital

Basel, CH-4031, Switzerland

Location

MeSH Terms

Conditions

Exploratory Behavior

Interventions

Citric AcidSaltsQuinineSodium GlutamateGlucose

Condition Hierarchy (Ancestors)

Behavior

Intervention Hierarchy (Ancestors)

CitratesTricarboxylic AcidsAcids, AcyclicCarboxylic AcidsOrganic ChemicalsInorganic ChemicalsCinchona AlkaloidsAlkaloidsHeterocyclic CompoundsQuinuclidinesHeterocyclic Compounds, Bridged-RingQuinolinesHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingGlutamic AcidGlutamatesAmino Acids, AcidicAmino AcidsAmino Acids, Peptides, and ProteinsAmino Acids, DicarboxylicHexosesMonosaccharidesSugarsCarbohydrates

Study Officials

  • Christoph Beglinger, MD

    University Hospital, Basel, Switzerland

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
BASIC SCIENCE
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 6, 2014

First Posted

October 3, 2014

Study Start

March 1, 2013

Primary Completion

October 1, 2013

Study Completion

October 1, 2013

Last Updated

October 3, 2014

Record last verified: 2014-09

Locations